Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study

Li XS, Wang M, Wang Z, Fan B, Tian MY, Filippazzo J, Lee Y, Mallela DP, Mao K, Liu Y, Lemaitre RN, Xie V, Diaz[...]

Tuning BMP-Regulated Cell Differentiation in the Aortic Media by Mutating Matrix Gla Protein

Cai X, Gunasinghe KKJ, Qi L, Zhang L, Wu X, Jing Z, Zhao Y, Kim H, Yao E, Hsiai T, Rahman T, Chee XW, Yao[...]